WT1 and acute myeloid leukemia: Quantitative assessment of WT1 as MRD has been used as a marker for pre-emptive DLI in AML patients after allo-HCT (52), and WT1 copies/104 Abelson cells in marrow cells has been suggested as the cutoff value (48).